Skip to main content
. 2022 Jan 24;12:1248. doi: 10.1038/s41598-022-05193-z

Figure 3.

Figure 3

Selumetinib combined with KRT-232 inhibits tumor growth in CRC PDX models. Female athymic nu/nu mice bearing C1035 PDXs were treated with vehicle, selumetinib 15 mg/kg, KRT-232 15 mg/kg or the combination of both. The other four PDX were treated with vehicle, selumetinib 25 mg/kg, KRT-232 15 mg/kg or the combination of both. Selumetinib and KRT-232 were both administered daily. The treatment was stopped at 28 days or when tumor diameter reached 1.5 cm. Left panel, individual tumor volume change (mm3). Middle panel, growth curve graphs demonstrating mean change in tumor volume percentage ± SEM. Right panel, event-free survival curves. The C1185 model did not have any events and is not shown here.